Howard Marks’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Howard Marks’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-134,000	Closed	-$48.2K	–	299
2023 Q1	$48.2K	Hold	134,000	–	–	﹤0.01%	294
2022 Q4	$119K	Hold	134,000	–	–	﹤0.01%	340
2022 Q3	$210K	Hold	134,000	–	–	﹤0.01%	376
2022 Q2	$269K	Sell	134,000 -16,000	-11%	-$27.7K	﹤0.01%	355
2022 Q1	$349K	Hold	150,000	–	–	﹤0.01%	348
2021 Q4	$697K	Buy	150,000 +16,000	+12%	+$99.3K	0.01%	326
2021 Q3	$1.02M	Hold	134,000	–	–	0.01%	243
2021 Q2	$1.3M	Sell	134,000 -186,000	-58%	-$1.48M	0.02%	179
2021 Q1	$2.65M	Buy	+320,000	New	+$3.38M	0.04%	163
2020 Q3	–	Sell	-100,500	Closed	-$631K	–	197
2020 Q2	$631K	Buy	+100,500	New	+$385K	0.01%	178

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Howard Marks's SRNE Position: Q2 2023 in Review

Howard Marks sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 134,000 shares — an estimated $48.2K sold.

Howard Marks first reported a position in SRNE in Q2 2020 and held it in 10 quarters. The position peaked at $2.65M in Q1 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Howard Marks reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Howard Marks sold 134,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $48.2K.
Howard Marks first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 10 quarters.
Howard Marks's Sorrento Therapeutics, Inc. position peaked at $2.65M in Q1 2021.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Oaktree Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.